Market News & Trends
Evonik Launches Ready-to-Use Powder Premix to Improve Processing, Appearance & Swallowability of Oral Drug Products With an Immediate-Release Profile
Evonik recently launched a new ready-to-use powder premix blend of its EUDRAGIT functional polymers used for oral products with an immediate-release profile. EUDRAGIT IR ReadyMix…
Catalent Launches Delayed/Enteric-Release Softgel for Pharmaceutical & Nutraceutical Applications
Catalent recently announced the launch of OptiGel DR technology for the formulation and manufacture of delayed/enteric-release softgels. The technology allows softgel capsules to be formed…
VBL Therapeutics Announces Additional New European Patent
VBL Therapeutics recently announced the European Patent Office (EPO) has granted Patent No. 3328401, which covers VBL’s proprietary investigational anti-MOSPD2 monoclonal antibodies to treat oncology…
First Patient Dosed in Phase 2 Trial to Treat Complications in COVID-19
Arch Biopartners Inc. recently announced it has dosed the first patient in the Phase 2 trial of its lead drug LSALT peptide, targeting prevention of…
PepTC Vaccines Publishes Positive Preclinical Results for COVID-19 Peptide Vaccine
PepTC Vaccines Limited, a subsidiary of Treos Bio Limited, recently announced the publication of positive preclinical results of its investigational PolyPEPI-SCoV-2 peptide vaccine. The study…
Castle Creek Biosciences Treats First Patient in Phase 1/2 Gene Therapy Trial
Castle Creek Biosciences, Inc. recently announced that the first adult patient has been dosed in a Phase 1/2 clinical trial evaluating FCX-013, the company’s investigational…
Beroni Group Announces Successful Completion of SARS-CoV-2 Pseudovirus Neutralization Assay for Treatment of COVID-19
Beroni Group recently announced successful completion of SARS-CoV-2 pseudovirus neutralization assay in collaboration with GenScript Biotech Corporation (HKSE:1548), a leading global biotechnology company. The assay…
Aptose Initiates Dosing of CG-806 in Patients With Acute Myeloid Leukemia
Aptose Biosciences Inc. recently announced dosing of the first patient with acute myeloid leukemia (AML) in a Phase 1 a/b clinical study with CG-806, the…
Takeda & Arrowhead Collaborate to Co-Develop & Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease
Takeda Pharmaceutical Company Limited and Arrowhead Pharmaceuticals Inc. recently announced a collaboration and licensing agreement to develop ARO-AAT, a Phase 2 investigational RNA interference (RNAi)…
Vaxart Announces Dosing First Subject in Phase 1 Clinical Trial of Its Oral Tablet COVID-19 Vaccine
Vaxart, Inc. recently announced the first subject has been dosed in its Phase 1 study of VXA-CoV2-1, an oral tablet COVID-19 vaccine candidate. “We are…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….